Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 4/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | PDE4A | P27815 | 3/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30583450 | 0.84 | PDE4D (1.00) | PDE4BPDE4DSMN1; SMN2NPC1RAB9A | |
| SCHEMBL2201643 | 0.84 | PDE4D (1.00) | PDE4BPDE4DSMN1; SMN2NPC1RAB9A | |
| SCHEMBL8511047 | 0.81 | PDE4B (0.62) | PDE4BPDE4DL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL2201890 | 0.80 | LMNA (0.64) | PDE4DL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL2938583 | 0.79 | MEN1 (0.69) | PDE4DL3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2197832 | 0.79 | EGLN1 (0.54) | PDE4BPDE4DL3MBTL1NPC1RAB9A | |
| SCHEMBL27920237 | 0.79 | KMT2A (0.63) | PDE4BPDE4DNPC1RAB9AMEN1 | |
| SCHEMBL2203454 | 0.77 | PDE4B (0.56) | PDE4BPDE4DL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL9609102 | 0.76 | PDE4B (0.59) | PDE4BPDE4DL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL2202029 | 0.75 | POLB (0.59) | SMN1; SMN2NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| CN-101765430-A | Novel pyrazole derivatives | HOFFMANN LA ROCHE | 2010-06-30 | — | — | CN | disclosed |
| EP-2182953-A2 | NEW PYRAZOL DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013211-A2 | NEW PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | PDE4B 607/4885PDE4D 814/4885L3MBTL1 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.